Analysts Mixed On Premium For Pharmacyclics
March 05, 2015 at 16:48 PM EST
AbbVie Inc (NYSE: ABBV) $21 billion deal to acquire Pharmacyclics, Inc. (NASDAQ: PCYC) Thursday drew mixed reviews from analysts and ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.